Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The transcriptional repressor EZH2 is implicated in control of cell proliferation in embryonic, immortalized and transformed cells. EZH2 expression in prostate cancer correlates with progression to hormone-refractory and metastatic disease, but it is unknown whether EZH2 plays a specific role in the acquisition of an advanced prostate cancer phenotype. METHODS: Using siRNA knockdown, we investigated the role of EZH2 in maintenance of prostate cancer cell proliferation and invasiveness. Using LNCaP cells with inducible EZH2 overexpression, we investigated whether EZH2 upregulation promotes an aggressive phenotype. RESULTS: Knockdown of endogenous EZH2 reduced proliferation of androgen-responsive and androgen-independent prostate cancer cells. EZH2 knockdown also inhibited prostate cancer cell invasion. However, overexpression of EZH2 in androgen-responsive cancer cells did not appreciably affect either proliferation or invasiveness. CONCLUSIONS: EZH2 promotes proliferation and invasion of prostate cancer cells, which can account for the correlation between EZH2 expression levels and an adverse prostate cancer prognosis.

Original publication

DOI

10.1002/pros.20550

Type

Journal article

Journal

Prostate

Publication Date

01/04/2007

Volume

67

Pages

547 - 556

Keywords

Androgen Antagonists, Anilides, Cell Growth Processes, Cell Line, Tumor, Cell Transformation, Neoplastic, DNA-Binding Proteins, Enhancer of Zeste Homolog 2 Protein, Histocytochemistry, Humans, Male, Neoplasms, Hormone-Dependent, Nitriles, Polycomb Repressive Complex 2, Prostatic Neoplasms, RNA, Small Interfering, Tosyl Compounds, Transcription Factors, Transcription, Genetic, Transfection